Being married could improve your likelihood of surviving a myocardial infarction and is associated with reduced length of hospital stay, according to research presented at the British Cardiovascular Society (BCS) conference (6–8 June, Manchester, UK). Researchers found that married people were 14% less likely to die after a myocardial infarction than single people. Married people were also, on average, likely to spend two fewer days in hospital than single people.
In collaboration with Association of Physician Assistants in Cardiovascular Surgery (APACVS), the Getinge Group has launched a new “Harvesting Heroes” campaign. The campaign seeks to recognise healthcare professionals in the field of cardiac surgery as well as celebrate 20 years since the endoscopic vessel harvesting technique was pioneered. The technique is used during coronary artery bypass grafting (CABG).
St Jude Medical’s CardioMEMS heart failure (HF) system has been added to the European Society of Cardiology (ESC) guidelines as a directed therapy management and monitoring tool for heart failure patients. The new 2016 ESC Clinical Practice Guidelines for the diagnosis and treatment of acute and chronic heart failure this year include pulmonary artery pressure monitoring with the CardioMEMS HF system.
Women diagnosed with migraines have a slightly increased risk of developing cardiovascular diseases, such as heart attacks and strokes, and are somewhat more likely to die from these conditions than women who do not have migraine, according to findings of a large study published in The BMJ.
Patient enrolment has been completed in The Medicine Company’s ORION-1 study of PCSK9si, its investigational RNA interference (RNAi) proprotein convertase subtilisin/kexin type 9 synthesis inhibitor (PCSK9si).
BioVentrix has received US Food and Drug Administration (FDA) investigational device exemption approval to initiate its pivotal ALIVE (American Less Invasive Ventricular Enhancement) clinical trial.
Royal Philips has received CE marking for its cardiac troponin I (cTnI) blood test with the Minicare I-20 handheld device. Minicare cTnI is designed to deliver lab-comparable test results in less than 10 minutes.
According to data presented at EuroPCR (17–20 May, Paris, France), a hybrid sirolimus-eluting stent (Orsiro, Biotronik) is non-inferior to a zotarolimus-eluting (Resolute Intergrity, Medtronic). The multicentre, randomised, controlled all-comers ORIENT trial enrolled 372 patients who received either Orsiro or Resolute Integrity in treatment of a wide variety of coronary heart disease. The primary endpoin was in-stent late lumen loss at nine months, an angiographic endpoint.
The Netherlands presidency of the European Council and representatives of the European Parliament have reached a political agreement on two draft regulations for medical devices. The new regulations are aimed at ensuring that medical devices and in vitro diagnostic medical devices are safe while allowing patients to benefit of innovative health care solutions in a timely manner. However, the agreement is subject to the approval by the Council’s Permanent Representatives Committee and of the Parliament’s ENVI committee.
The heart rate may be an indicator of a person’s life expectancy. A research team at the Technical University of Munich (TUM) (Munich, Germany) has to this end analysed an effect which at first seems paradoxical: Minor irregularities in the heartbeat are indicative of a healthy body. A clinical study confirmed a strong correlation between this phenomenon and the survival prospects of heart attack patients. The new methods of measurement may soon be applied in medical practice.
Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016.
ResMed has announced primary results from a multicentre, randomised controlled phase II trial—CAT-HF—presented at the European Society of Cardiology’s 2016 Annual Heart Failure Congress.
Medinol has announced that the BioNIR has met its non-inferiority primary end point of angiographic in-stent late loss at six months in the NIREUS trial. The prospective, multicentre, randomised, non-inferiority pivotal study compared it to Medtronic’s Resolute Integrity stent.
A session, sponsored by Alvimedica Medical Technologies, discussing treatment options for percutaneous coronary intervention (PCI) in diabetic patients, took place at EuroPCR (16-20th May 2016, Paris, France).
First-in-human data presented at EuroPCR 2016 have demonstrated that haemodynamic data from HeartFlow may help predict which coronary plaques have the potential to rupture. The results were part of a study designed to determine whether use of HeartFlow technology could predict risk of developing acute coronary syndrome (ACS), a condition associated with sudden, reduced blood flow to the heart. The study was led by Bon-Kwon Koo of Seoul National University Hospital, Korea.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos